•
Jun 30, 2021
Black Diamond Therapeutics Q2 2021 Earnings Report
Reported financial results for the second quarter ended June 30, 2021 and provided a corporate update.
Key Takeaways
Black Diamond Therapeutics reported its Q2 2021 financial results, highlighting the advancement of its clinical and pre-clinical pipeline, including BDTX-189, BDTX-1535, BRAF, and FGFR programs. The company's cash, cash equivalents, and investments totaled $263.5 million as of June 30, 2021.
Presented initial Phase 1 clinical data for BDTX-189 at ASCO Annual Meeting and is on track to initiate Phase 2 portion of MasterKey-01 study in the second half of 2021.
Presented pre-clinical data for BDTX-1535 at AACR Annual Meeting and is on track to enter the clinic in 2022.
Early-stage pipeline programs targeting BRAF and FGFR remain on track for IND filing in 2022.
Appointed Mark Velleca, M.D., Ph.D., to Board of Directors.